ABPI and our Regional Industry GroupsAndy Riley, Partnerships Manager, Midlands and East

Real world data and e-health

ABPI landscape and policy map

Innovation, Health and Wealth

value based pricing

PPRS

Commissioning

Reputation

UK Competitiveness

NHS Partnerships

Discovery Development Approval Fair Price Access Uptake Patients

Supply ChainPartnerships for research

Animal research

EU Influence

Clinical research

Regulatory framework and MHRA

Manufacturing and the environment

Schools, higher education and skills

Intellectual property and patent

Pharmacovigilance

Patient Group Forum

Medicines Optimisation

HTA

Our partnerships for delivery

• We have an MOU with the NHS Confederation, ABHI and Medilinks to support the implementation of Innovation, Health and Wealth

http://www.nhsconfed.org/priorities/latestnews/Pages/NHS-Confederation-joins-ABPI-ABHI-innovation-project.aspx

• This strategic agreement aims to increase the adoption and diffusion of proven technologies in areas of high clinical need to deliver high quality patient outcome and efficiency gains

• It includes showcasing best practice for joint working, judged by an independent panel – our first launch event was in February

• We work on policy at a national level with a range of organisations, including the DoH, NHS England, NICE, Royal Colleges and others

Our vision

NHS Partnerships Team established in 2012, led by Carol Blount, our director:

– Kevin Blakemore, National Manager– Regional Managers:

– Di Vegh (South)– Harriet Lewis (North)– Andy Riley (Mids and East)– Karen Thomas (London)

– Mike Ringe, Therapy Group Manager– Terry Harrison, consultant– Industry secondee

currently Farid Bidgoli from AZ

Industry as an integral part of the NHS’s solution to the delivery of better patient outcomes

NHS Partnership team priorities

We are:- Identifying and sharing local NHS issues, organisational and policy changes with member companies- Taking the lead on themes from the Innovation, Health and Wealth and other key priorities, e.g. medicines optimisation- Demonstrating the value of medicines as an opportunity to improve outcomes rather than as a cost pressure to commissioners and providers- Supporting companies in the development of Joint Working projects

We aren’t: - Promoting a particular company/ therapy area or product- Trying to improve your market share- Replicating or ‘competing’ with member company field teams- The only way that the NHS can engage with pharma